GRFS
$8.02
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Recent News
Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns
If you are wondering whether Grifols at €9.22 is a bargain or a value trap, you are in the right place to size up what the current share price might actually represent. The stock has recently been weak, with a 7 day return of an 8.4% decline, a 30 day return of a 15.6% decline, a year to date return of a 17.7% decline, and a 5 year return of a 57.0% decline, which may have changed how investors see both its potential and its risks. Recent headlines around Grifols have mainly focused on its...
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
European equities traded in the US as American depositary receipts were lower late Friday morning, d
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
Grifols slides as Morgan Stanley downgrades on uncertain growth outlook
Investing.com -- Grifols shares slipped after Morgan Stanley downgraded the Spanish healthcare group, citing weaker visibility on medium-term revenue growth and headwinds in key product segments.